The name has been revealed for a state-of-the-art proton beam therapy (PBT) cancer centre that is being built in Northumberland.
The Rutherford Cancer Centres will offer patients a comprehensive range of treatments.
Three centres are currently under development – they will be located at the Earth Balance wellness site in Bomarsund, Newport in South Wales and Reading, Berkshire.
When construction work started for the Bomarsund facility last August, Proton Partners International said it is expected to be operational by February 2018.
According to the NHS website, PBT is ‘useful for treating types of cancer in critical areas – when it is important to reduce damage to surrounding tissue as much as possible’.
In addition to PBT, imaging, chemotherapy, traditional radiotherapy and well-being services will be available.
Treatment at The Rutherford Cancer Centres will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.
Professor Gordon McVie, chairman of Proton Partners International, said: “We’re delighted to announce the creation of The Rutherford Cancer Centres.
“Proton Partners International is committed to transforming cancer care in the UK. The Rutherford name is synonymous with a major breakthrough in cancer treatment and therefore we felt that this was a fitting identity for our treatment centres.
“With cancer on the rise, there is a growing need for patients to be offered a holistic and sophisticated level of cancer care.
“Patients at The Rutherford Cancer Centres will have access to a wide range of cancer services and a treatment plan will be implemented on an individual basis.”
Mike Moran, chief executive officer of Proton Partners International, added: “We are working with the world’s leading technology partners to ensure that our centres are equipped with the latest cancer technology.
“Our centres will have the capacity to treat 500 unique patients a year.
“We will also network our centres to ensure the data they will provide can play a significant role in cancer research.
“We are committed to undertaking a genomics programme which will collate, analyse and distribute data through our research facility at the Life Sciences Accelerator centre in Liverpool.”